Skip to main content
    K

    Krystal Biotech Inc (KRYS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $297.90
    -7.33 (-2.40%)

    Market Cap: $9.05B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Krystal Biotech Inc (KRYS) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Krystal Biotech (KRYS) trades at 40.4x trailing earnings and 18.8x sales. Its P/B of 6.1x is above its 5-year median of 4.9x. Its forward P/E is 39.8x. The median P/E across 3 similar companies is 39.6x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 1.5% higher over the next year. Its free cash flow yield is 3.5%.

    MultipleValue
    P/E (trailing)40.4x
    Forward P/E39.8x
    Price to sales18.8x
    Price to book6.1x
    EV/EBITDA35.7x
    Price to FCF28.4x
    EV/FCF27.0x
    PEGN/A
    FCF yield3.5%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 52.5% above 4.0x.

    MultipleCurrent5-year median10-year median
    P/B6.1x4.9x4.0x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 110 months (10-year).

    Valuation History

    Over the 4 of the 9 year ends shown that have a P/S, its P/S ranged from 15.6x in 2024 to 274.5x in 2018.

    Year endPriceP/EP/SP/B
    2025$246.5436.0x18.5x6.1x
    2024$156.6646.1x15.6x4.9x
    2023$124.06N/A70.2x4.6x
    2022$79.22N/AN/A3.9x
    2021$69.95N/AN/A2.6x
    2020$60.00N/AN/A4.1x
    2019$55.38N/AN/A4.7x
    2018$20.78N/A274.5x2.5x
    2017$10.52N/AN/A2.2x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About KRYS

    What is KRYS's forward P/E ratio?

    Krystal Biotech has a forward P/E ratio of 39.8x.

    Is KRYS stock overvalued?

    GNG's valuation label for KRYS is Undervalued. Its P/E of 40.4x compares with a median of 39.6x across 3 similar companies.

    What is KRYS's price to sales ratio?

    Krystal Biotech has a price to sales ratio of 18.8x.